| 标题 |
 LOTUS investigators. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
| 备注 |
要lancet oncology期刊的版本
💡 该求助存在备注，如果存在信息冲突，请以备注为准
|
| 网址 | |
| DOI | |
| 其它 | Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3. Epub 2017 Aug 8. Erratum in: Lancet Oncol. 2018 Dec;19(12):e667. doi: 10.1016/S1470-2045(18)30845-3. PMID: 28800861; PMCID: PMC5626630. |
| 求助人 | |
| 下载 | 求助已完成，仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)
wwww
东方元语
Nole
cdercder
xing_xing
Dean
馆长
Maestro_S
学术文献互助
aajhajkahna
奔跑
sagitar
安详香旋
无奈的梦凡
渡人舟
猪猪hero
onlyone
OK
七听
aaaa
皖公网安备34019202002308
